title: Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
abstract: We reported the results of a clinical pharmacological study of MC710 (a mixture of plasma-derived FVIIa and FX) in haemophilia patients with inhibitors during a non-haemorrhagic state. This report provides the results of a clot waveform analysis (CWA) and thrombin generation test (TGT) using blood samples obtained in this study. CWA and TGT were conducted using blood samples obtained from a pharmacokinetic and pharmacodynamic study in which MC710 (five dose rates: 20, 40, 80, 100 and 120 μg kg(-1)) was compared with NovoSeven (120 μg kg(-1)) and FEIBA (two dose rates: 50 and 75 U kg(-1)) as control drugs in 11 haemophilia patients with inhibitors without haemorrhagic symptoms. CWA showed that MC710 provided significantly greater improvement than the control drugs in activated partial thromboplastin time (APTT) at 80 μg kg(-1); maximum clot velocity and maximum clot acceleration were more enhanced by MC710 than by control drugs. TGT revealed that MC710 significantly shortened the initiation time of thrombin generation in comparison to FEIBA and induced greater thrombin generation potency than NovoSeven. It was not clear whether or not MC710 caused significant dose-dependent changes in the two measurements; however, differences between MC710 and the control drugs were clarified. MC710 was confirmed to have superior coagulation activity and thrombin productivity and is expected to have superior bypassing activity.
authors.affiliation: Department of Paediatrics, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan. a-shirahata@kitakyu-hp.or.jp
authors.forename: A
authors.initials: A
authors.lastname: Shirahata
authors.forename: K
authors.initials: K
authors.lastname: Fukutake
authors.forename: J
authors.initials: J
authors.lastname: Mimaya
authors.forename: J
authors.initials: J
authors.lastname: Takamatsu
authors.forename: M
authors.initials: M
authors.lastname: Shima
authors.forename: H
authors.initials: H
authors.lastname: Hanabusa
authors.forename: H
authors.initials: H
authors.lastname: Takedani
authors.forename: Y
authors.initials: Y
authors.lastname: Takashima
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
authors.forename: A
authors.initials: A
authors.lastname: Tawa
authors.forename: S
authors.initials: S
authors.lastname: Higasa
authors.forename: N
authors.initials: N
authors.lastname: Takata
authors.forename: M
authors.initials: M
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Kawakami
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: H
authors.initials: H
authors.lastname: Saito
mesh_terms: D000293:Adolescent; D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D001780:Blood Coagulation Tests / Q000379:methods; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015942:Factor VIIa / Q000494:pharmacology*; D005170:Factor X / Q000494:pharmacology*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007564:Japan; D008297:Male; D013917:Thrombin / Q000378:metabolism; D055815:Young Adult
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005170:Factor X; D015942:Factor VIIa; D013917:Thrombin